On 25 March 2014 Sinclair IS Pharma PLC, the international specialty pharmaceutical company, announced that it had entered into agreements to acquire the global rights to Ellansé™, a collagen bio-stimulating dermal filler product range, through the acquisition of AQTIS Medical™, Utrecht, The Netherlands.
Sinclair is an international specialty pharmaceutical company centered on Dermatology, in particular – Aesthetics, Wound care, and Skin care.
The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing international division concentrated on the emerging markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.
“…The Ellansé™ brand comprises a range of latest generation fully bioresorbable polycaprolactone (PCL) dermal fillers for the face and hands, which combine the immediate correction of wrinkles and folds as well as volumisation through the stimulation of collagen. The duration of activity is highly predictable and at up to 4 years has a very competitive lifespan although Sinclair expects the bulk of sales to be for 1 or 2 year duration products…”
Scan the QR code and read the entire Sinclair IS Pharma Press Release
About Sinclair IS Pharma plc – BOX OUT
Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular Aesthetics, Wound care, and Skin care. The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.
For more information contact 0207 46769
